Henry Schein (HSIC) Expected to Announce Earnings on Tuesday

Henry Schein (NASDAQ:HSIC) is projected to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $1.30 per share and revenue of $3.3446 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Henry Schein Trading Down 0.3%

NASDAQ HSIC opened at $78.19 on Tuesday. The company has a market capitalization of $9.20 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. Henry Schein has a 12 month low of $60.56 and a 12 month high of $82.80. The company’s fifty day moving average price is $77.20 and its two-hundred day moving average price is $71.37.

Institutional Investors Weigh In On Henry Schein

Large investors have recently made changes to their positions in the company. Sargent Investment Group LLC acquired a new position in shares of Henry Schein during the fourth quarter valued at approximately $214,000. Davis R M Inc. bought a new position in Henry Schein during the 4th quarter valued at $219,000. Mitchell Mcleod Pugh & Williams Inc. acquired a new position in shares of Henry Schein during the 4th quarter valued at $200,000. CIBC Private Wealth Group LLC increased its position in shares of Henry Schein by 125.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,260 shares of the company’s stock valued at $216,000 after purchasing an additional 1,812 shares during the period. Finally, Advisory Services Network LLC bought a new stake in shares of Henry Schein in the 3rd quarter worth $147,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

HSIC has been the topic of several research analyst reports. Morgan Stanley increased their price target on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Barrington Research set a $79.00 price target on Henry Schein and gave the company an “outperform” rating in a report on Wednesday, November 5th. Wells Fargo & Company upped their price target on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Henry Schein currently has an average rating of “Hold” and a consensus price target of $76.42.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.